Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep …
WEB3 days ago · On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA ...
Vivos Therapeutics Announces Pricing of $4.3 Million Registered …
WEB2 days ago · LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) …
WEB3 days ago · Kirk Huntsman, Chairman and CEO of Vivos, stated, “The FDA 510(k) clearance announced today is, to our knowledge, the first time any oral medical device has ever been approved to treat moderate ...
FDA Clears Vivos Therapeutics Pediatric Sleep Apnea and Snoring …
WEB2 days ago · Vivos Therapeutics, a leading medical device and technology company specializing in the development and commercialization of proprietary treatments for sleep related breathing disorders (SRBDs), including obstructive sleep apnea (OSA), received U.S. Food and Drug Administration (FDA) 510(k) clearance to treat moderate to severe OSA and snoring in children using Vivos’ proprietary flagship ...
Vivos surges on FDA nod for pediatric sleep apnea device
WEB3 days ago · JHVEPhoto. Shares of Vivos Therapeutics (NASDAQ: VVOS) climbed on Wednesday after MedTech announced the FDA's 510 (k) clearance for its DNA appliance as a treatment for children with obstructive ...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) …
WEB3 days ago · Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now ...
Vivos Therapeutics Announces Pricing of $4.3 Million
WEB2 days ago · LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Vivos Therapeutics Gets FDA 510(k) Clearance To Treat Pediatric …
WEB3 days ago · Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring GlobeNewswire 1h Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M
Vivos Therapeutics Announces Positive Results From 7-Month …
WEBJun 27, 2024 · The pilot program results announced today provide evidence of the significant potential of this new model for Vivos. The pilot program was conducted over a 7-month period in seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles.
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for …
WEBNov 29, 2023 · With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new.
Skip to content